Sermorelin: What It Is, Where to Get It Prescribed, and What It Costs

Growth-hormone-releasing hormone, GHRH, is a 44-amino-acid peptide made in the hypothalamus whose job is to tell the pituitary to release growth hormone. Sermorelin is the first 29 of those 44 amino acids with an amide on the end — GHRH(1-29)-NH2 in the literature — the shortest fragment of the native hormone that keeps its full activity. It is supplied as an acetate salt. The practical point is that sermorelin is a truncated copy of a signal the hypothalamus sends to the pituitary every night, acting on the same receptor the natural hormone acts on.

Sermorelin is unusual among compounded peptides because it has a full regulatory history. As Geref it was approved by the FDA twice: in 1990 as a diagnostic test of whether a child's pituitary could secrete growth hormone, and in 1997 as a treatment for idiopathic growth hormone deficiency in children with growth failure. It was discontinued by its manufacturer in 2008 for commercial reasons — not for any safety or effectiveness problem, as the FDA later stated in writing. The full history is under "Where sermorelin stands with the FDA right now." That matters for reading the research here: sermorelin has randomised human trials and an adverse-event profile collected under a regulator's eye, which most peptides on this site do not.

It is not growth hormone. Sermorelin contains none; it asks the pituitary to release what it makes, and if the pituitary cannot respond it does nothing — which is why it worked as a diagnostic. It is not an anabolic steroid and does not suppress testosterone. It is not a GLP-1 medication or a weight-loss drug. And it is not the same as ipamorelin or CJC-1295, even though it is often prescribed alongside them; those act through different receptors, as explained under "How sermorelin compares."

Somatotrophs are the pituitary cells that make and store growth hormone, and they carry a GHRH receptor. Sermorelin binds it, raises cyclic AMP inside the cell and triggers release of stored growth hormone. Human studies describe this as fast: in the Khorram trial in the Journal of Clinical Endocrinology and Metabolism in 1997, a nightly subcutaneous dose of a GHRH(1-29) analogue produced a measurable rise in growth hormone within ten minutes, lasting about two hours.

Growth hormone is released in bursts, the largest in the first hours of deep sleep. Injected growth hormone replaces that pattern with a sustained elevation, which is part of why it produces fluid retention, joint pain and insulin resistance at higher doses. Sermorelin produces a pulse followed by a return to baseline: National Institute on Aging work in 1992 described GHRH(1-29) in older men as raising the amplitude of their growth hormone peaks toward those of young men while keeping the pulsatile pattern intact.

Because the pituitary is still doing the releasing, the body's brakes still work: somatostatin still inhibits release, and rising IGF-1 still feeds back on the hypothalamus and pituitary. That is why a secretagogue is described as self-limiting in a way exogenous growth hormone is not. It does not mean "cannot be overdone" — physicians still monitor IGF-1.

Most of what growth hormone does in adults it does indirectly, by stimulating the liver to produce insulin-like growth factor 1, which carries the signal to muscle, bone and connective tissue. This is why IGF-1 is the marker physicians track: a single growth hormone sample is nearly meaningless because of pulsatility, while IGF-1 integrates the previous days' secretion. Human trials report IGF-1 rising within two to four weeks of nightly GHRH dosing in older adults.

This is where the strongest evidence sits, and the population was children. The pivotal work was the Geref International Study Group trial in the Journal of Clinical Endocrinology and Metabolism in 1996: 110 previously untreated prepubertal children with growth hormone deficiency received once-daily bedtime GHRH(1-29) for up to a year in a multicentre open-label study. Mean height velocity roughly doubled over the first six months, bone age advanced in proportion to height rather than ahead of it, fasting glucose did not change, and the drug was reported as well tolerated. A 1999 review in BioDrugs (Prakash and Goa) summarised the programme: sermorelin produced growth in most children with idiopathic GHD, though somewhat less than recombinant growth hormone did — one reason it lost the commercial argument.

Before Geref was a treatment it was a test: a single dose with blood drawn afterwards showed whether the pituitary could release growth hormone when told to. That diagnostic use is settled human pharmacology and the clearest demonstration that sermorelin does what it is described as doing.

Growth hormone secretion falls with age, and a series of 1990s trials asked whether GHRH could reverse that. The National Institute on Aging study (Journal of Clinical Endocrinology and Metabolism, 1992) gave GHRH(1-29) twice daily to healthy men in their late sixties for fourteen days and reported 24-hour growth hormone and IGF-1 rising to levels no longer significantly different from men in their twenties, with no change in fasting glucose or blood pressure.

The Johns Hopkins group (Vittone and colleagues, Metabolism, 1997) gave single nightly injections to eleven healthy men aged 64 to 76 for six weeks: nocturnal growth hormone rose, IGF-1 and body composition did not change, and three of seven strength and endurance measures were reported as better. The authors concluded a single nightly dose was less effective than multiple daily doses at producing IGF-1-mediated effects.

The Khorram, Laughlin and Yen trial (Journal of Clinical Endocrinology and Metabolism, 1997) is the longest: randomised, placebo-controlled, sixteen weeks of nightly GHRH(1-29) analogue in nineteen men and women aged 55 to 71. Nocturnal growth hormone rose in both sexes; IGF-1 rose within two weeks, stayed up for twelve, then drifted back toward baseline by sixteen. These are endocrine endpoints, not reports of people feeling or performing differently.

A University of Washington group also reported in Neurobiology of Aging in 2006 that six months of daily GHRH versus placebo in 89 healthy adults around age 68 was associated with better scores on several cognitive measures; the larger 2012 follow-on trial used tesamorelin, a different GHRH analogue, and belongs to the class rather than to this product.

The precise statement is this. Sermorelin has randomised and controlled human trials, but they were run in children with growth hormone deficiency and in small groups of healthy older adults, and their endpoints were height velocity, hormone levels and laboratory measures. There is no large randomised trial of sermorelin in adults for body composition, recovery, sleep quality or "anti-aging" as an outcome. What exists for those uses is the endocrine trials above — which establish that sermorelin raises a person's own growth hormone and, with adequate dosing, IGF-1 — plus prescriber experience. That is a much better evidence base than "animal and cell studies," and it is honest to say so. It is also honest to say the trials that would show whether an adult on sermorelin for six months looks, sleeps or recovers differently from one on placebo have not been done.

• It does not establish a body-composition effect in adults. The trials that measured it were short, and the six-week nightly-dose trial found no change.
• It does not establish an effect on sleep quality as a treatment endpoint. The physiology linking GHRH and slow-wave sleep is real; that is not the same as an outcome.
• It does not establish how long the endocrine change persists. The sixteen-week trial saw IGF-1 drift back toward baseline on treatment.
• It does not establish safety over years of continuous adult use.
• It does not establish efficacy for any adult indication as an FDA-approved treatment. The approved indication was in children, and that approval no longer exists.

The pharmacology is immediate — the growth hormone pulse happens the first night — but nothing you can feel tracks a single pulse. What people most often report early is sleep: falling asleep faster or sleeping more deeply on injection nights. Some report nothing at all, which is normal. The trials show IGF-1 beginning to rise within two weeks where dosing is adequate, a blood-test change rather than a felt one.

This is the window in which prescribers describe the things people started for — recovery between training sessions, energy, skin — if they occur. It is also when a physician would typically recheck IGF-1. If it has not moved, the dose or the schedule is the conversation, not more weeks of the same.

The sixteen-week trial saw IGF-1 drift back toward baseline on treatment, a reminder that the feedback loops sermorelin preserves also limit it. Prescribers manage this in different ways, and the 28-day refill cycle exists partly so the physician sees the pattern. Body-composition change, where prescribers describe it, is gradual and depends on training and diet as much as on the injection.

No rebound suppression is described, because sermorelin does not shut down the axis the way exogenous growth hormone does. Pulses return to whatever they were before. Whatever changed on treatment persists only to the extent the underlying tissue changed.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated. The dose is given at night because that is when the pituitary's own largest pulse occurs, and Monday through Friday rather than every day because prescribers commonly build in two nights off each week. Your directions are what apply.

20 doses at five nights a week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label. How to store peptides covers this properly.

Both act on the GHRH receptor. Tesamorelin is the full 44-amino-acid GHRH with a modification that slows its breakdown. It is the active ingredient of Egrifta, an FDA-approved drug for excess abdominal fat in HIV-associated lipodystrophy, and has randomised adult trials including the 152-person cognition trial above. Sermorelin is the shorter, older, less expensive molecule with paediatric trials and a discontinued approval. A physician choosing between them is weighing cost against adult trial data.

Different receptors. Sermorelin and CJC-1295 both act on the GHRH receptor; CJC-1295 is a longer-acting analogue, and a 2006 paper in the Journal of Clinical Endocrinology and Metabolism reported growth hormone pulsatility persisting during continuous stimulation with it. Ipamorelin acts on the ghrelin receptor, a separate door into the same cell, and is usually combined with a GHRH analogue rather than used instead of one — hence CJC-1295 / Ipamorelin and Ipamorelin + Sermorelin, which uses sermorelin as the GHRH side. Neither combination has adult outcome trials.

Identical medication. The pepti Pen is a pre-filled cartridge in a reusable click-dial injector, dosed in clicks rather than drawn from a vial with a syringe. It costs more and it removes the draw step. Neither is clinically better.